Cover Image
Market Research Report

Bespoke Cancer Treatment Using Vaccines: Exploring the Possibility of Changing the Treatment Paradigm

Published by DelveInsight Business Research LLP Product code 924081
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
Bespoke Cancer Treatment Using Vaccines: Exploring the Possibility of Changing the Treatment Paradigm
Published: will be released March 4, 2020 Content info:
Description

Despite of the expanding oncology pipeline, cancer vaccines contribute only to a minor share of total oncology-attributed revenues owing to the limited number of approved products. Although, the FDA approved a personalized vaccine Sipuleucel-T (Provenge) for men with metastatic prostate cancer in 2010. Cancer vaccine development is well known for its high development costs and risks, low historical rates of investment return, high probability of failures arising in ventures, partnerships and alliances. The cost of reimbursement for novel oncology therapies is not universally acceptable to payers limiting the potential for a global expansion, market access and reducing probability of commercial success.

However, a positive light can be thrown on the upcoming cancer therapeutic vaccines, which boosts the immune system's ability to recognize and destroy antigens. The current research and development is focussed more on developing personalized vaccines. These types of vaccines are produced from the person's tumor sample. Other cancer vaccines target specific cancer antigens and are given to people whose tumors have those antigens on the surface of the tumor cells. The major vaccine types in development are peptide vaccines, dendritic cell vaccines, mRNA and DNA based vaccines and neo-antigen vaccines through novel technology platforms.

The upcoming market of cancer vaccines is blooming with promising therapeutic vaccine. In terms of the cancer indications, the most benefitted one's with respect to a good number of upcoming vaccines by major key players are prostate cancer (Advantagene), NSCLC (OSE immunotherapuetics), pancreatic cancer (Nantkwest), melanoma, followed by DLBCL, Breast cancer and colorectal cancers. Other cancers such as Bladder cancer, Glioblastoma's, Microsatellite Instability-High Cancers, Anal and Rectal cancers are also under the light of development with equally potential therapeutic vaccines.

Highlighting the major key players' along with their potential developments in trial, such as Advantagene's Prostatak and OSE immunotherapeutics' Tedopi will be the first to market position due to their early launches in the United States, EU5 Countries followed by Japan. While other potential players are Moderna and Neon Therapeutics.

Out of the 20+ promising therapeutic cancer vaccines ((there are 100+ in total), including 14+ indications in high stages of development most of them are targeting recurrent and advanced stages of cancer, except the one being developed for first line treatment of patients with Glioblastoma Multiforme.

Another major key players are Nantkwest and Immunovaccine technologies, in terms of targeting the maximum number of cancer indications. Nantkwest's hank vaccine is being evaluated in combination with avelumab for Triple Negative Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma and Pancreatic Cancer along with few other indications in early stages of testing. While Immunovaccine technologies's DPX-Survivac (Survivin) is being developed in combination with Keytruda for Ovarian cancer, DLBCL, NSCLC, bladder, HCC, melanoma along with few other cancers.

These budding vaccines are majorly tested in combination with radiation therapy, chemotherapy, adjuvants with either their respective standard of care (SOC) therapies or I-O therapies involving PD-1/PD-L1 such as pemrolizumab, nivolumab etc. It's mesmerizing that not just the upcoming vaccine market is expected to boom in the coming years, but along it will also strengthen the already existing market of blockbuster PD-1/PD-L1 inhibitors, fulfilling the best choice for adjuvants.

In conclusion, therapeutic cancer vaccines have the potential to address several unmet needs that persist in cancer treatment paradigm currently. It's likely that they will prove their value as high efficacy, promising and low-toxicity treatment options for early-stage disease and by enhancing the efficacy of existing regimens in late-stage disease.

In this report we have captured the commercial potential of all potential cancer treatment vaccine targeting multiple indications in next 10-15 years.

Table of Contents

TABLE OF CONTENTS

1. KEY INSIGHTS

2. CANCER VACCINES MARKET OVERVIEW AT A GLANCE

  • 2.1. MARKET SHARE (%) DISTRIBUTION OF CANCER VACCINES IN 2017
  • 2.2. MARKET SHARE (%) DISTRIBUTION OF CANCER VACCINES IN 2030

3. DISEASE BACKGROUND AND OVERVIEW: CANCER VACCINES

  • 3.1. INTRODUCTION
  • 3.2. STRATEGIES FOR CANCER VACCINE IMMUNOTHERAPY
  • 3.3. TYPES OF TUMOR VACCINES
    • 3.3.1. Whole-cell vaccines
    • 3.3.2. Antigen Based Vaccines
    • 3.3.3. Antigen Presenting Cell Vaccines
    • 3.3.4. Nonspecific and Cytokine Strategies
  • 3.4. CANCER VACCINE ANTIGENS
    • 3.4.1. Tumor-associated antigens
    • 3.4.2. Oncogenic viral antigens
    • 3.4.3. Neoantigens
  • 3.5. VACCINE VECTORS
    • 3.5.1. Cellular vaccines
    • 3.5.2. Peptide vaccines
    • 3.5.3. Viral vector vaccines
    • 3.5.4. DNA and RNA vaccines
  • 3.6. COMBINATIONS WITH OTHER THERAPIES
  • 3.7. MARKETED CANCER VACCINES
  • 3.8. RESEARCH
  • 3.9. SIDE EFFECTS OF CANCER VACCINES

4. MARKETED DRUGS

  • 4.1. MARKETED DRUGS KEY-CROSS COMPETITION
  • 4.2. PROVENGE (SIPULEUCEL-T): DENDREON CORPORATION/SANPOWER GROUP
    • 4.2.1. Drug Description
    • 4.2.1. Regulatory Milestones
    • 4.2.2. Other Development Activities
    • 4.2.3. Safety and Efficacy
    • 4.2.4. Product Profile

5. EMERGING DRUGS

  • 5.1. KEY CROSS COMPETITION
  • 5.2. KEY CROSS COMPETITION OF PHASE I VACCINES
  • 5.3. PROSTATAK: ADVANTAGENE
    • 5.3.1. Product Description
    • 5.3.2. Other Developmental Activities
    • 5.3.3. Clinical Development
    • 5.3.4. Product Profile
  • 5.4. TEDOPI (OSE2101): OSE IMMUNOTHERAPEUTICS
    • 5.4.1. Product Description
    • 5.4.2. Other Developmental Activities
    • 5.4.3. Clinical Development
    • 5.4.4. Product Profile
  • 5.5. DCVAC/OVCA: SOTIO
    • 5.5.1. Product Description
    • 5.5.2. Other Developmental Activities
    • 5.5.3. Clinical Development
    • 5.5.4. Product Profile
  • 5.6. DCVAC/PCA: SOTIO
    • 5.6.1. Product Description
    • 5.6.2. Other Developmental Activities
    • 5.6.3. Clinical Development
    • 5.6.4. Product Profile
  • 5.7. AXALIMOGENE FILOLISBAC (ADXS11-001; ADXS-HPV): ADVAXIS
    • 5.7.1. Product Description
    • 5.7.2. Other Developmental Activities
    • 5.7.3. Clinical Development
    • 5.7.4. Product Profile
  • 5.8. HEPCORTESPENLISIMUT-L (HEPKO-V5; V5): IMMUNITOR
    • 5.8.1. Product Description
    • 5.8.2. Other Developmental Activities
    • 5.8.3. Clinical Development
    • 5.8.4. Product Profile
  • 5.9. DCVAC/LUCA: SOTIO
    • 5.9.1. Product Description
    • 5.9.2. Other Developmental Activities
    • 5.9.3. Clinical Development
    • 5.9.4. Product Profile
  • 5.10. VX-001: VAXON BIOTECH
    • 5.10.1. Product Description
    • 5.10.2. Other Developmental Activities
    • 5.10.3. Clinical Development
    • 5.10.4. Product Profile
  • 5.11. TLPLDC VACCINE: ELIOS THERAPEUTICS
    • 5.11.1. Product Description
    • 5.11.2. Other Developmental Activities
    • 5.11.3. Clinical Development
    • 5.11.4. Product Profile
  • 5.12. MRNA-4157 + PEMBROLIZUMAB: MODERNATX
    • 5.12.1. Product Description
    • 5.12.2. Other Developmental Activities
    • 5.12.3. Clinical Development
    • 5.12.4. Product Profile
  • 5.13. GRANITE (GRT-C901) + SLATE (GRT-R902): GRITSTONE ONCOLOGY
    • 5.13.1. Product Description
    • 5.13.2. Other Developmental Activities
    • 5.13.3. Clinical Development
    • 5.13.4. Product Profile
  • 5.14. HANK VACCINE: NANTKWEST
    • 5.14.1. Product Description
    • 5.14.2. Other Developmental Activities
    • 5.14.3. Clinical Development
    • 5.14.4. Product Profile
  • 5.15. GVAX VACCINE : ADURO BIOTECH
    • 5.15.1. Product Description
    • 5.15.2. Other Developmental Activities
    • 5.15.3. Clinical Development
    • 5.15.4. Product Profile
  • 5.16. DC VACCINE: AIM IMMUNOTECH
    • 5.16.1. Product Description
    • 5.16.2. Other Developmental Activities
    • 5.16.3. Clinical Development
    • 5.16.4. Product Profile
  • 5.17. POLYPEPI1018 VACCINE: TREOS BIO
    • 5.17.1. Product Description
    • 5.17.2. Other Developmental Activities
    • 5.17.3. Clinical Development
    • 5.17.4. Product Profile
  • 5.18. RV001V: RHOVAC
    • 5.18.1. Product Description
    • 5.18.2. Other Developmental Activities
    • 5.18.3. Clinical Development
    • 5.18.4. Product Profile
  • 5.19. SURVIVIN (DPX-SURVIVAC VACCINE): IMMUNOVACCINE TECHNOLOGIES
    • 5.19.1. Product Description
    • 5.19.2. Other Developmental Activities
    • 5.19.3. Clinical Development
    • 5.19.4. Product Profile
  • 5.20. AD-MAGEA3 AND MG1-MAGEA3: TURNSTONE BIOLOGICS
    • 5.20.1. Product Description
    • 5.20.2. Other Developmental Activities
    • 5.20.3. Clinical Development
    • 5.20.4. Product Profile
  • 5.21. DENDRITIC CELL-BASED P53 VACCINE + NIVOLUMAB + IPILIMUMAB: MULTIVIR
    • 5.21.1. Product Description
    • 5.21.2. Other Developmental Activities
    • 5.21.3. Clinical Development
    • 5.21.4. Product Profile
  • 5.22. ISA101/ISA101B: ISA PHARMACEUTICALS
    • 5.22.1. Product Description
    • 5.22.2. Other Developmental Activities
    • 5.22.3. Clinical Development
    • 5.22.4. Product Profile
  • 5.23. GEN-009 ADJUVANTED VACCINE: GENOCEA BIOSCIENCES
    • 5.23.1. Product Description
    • 5.23.2. Other Developmental Activities
    • 5.23.3. Clinical Development
    • 5.23.4. Product Profile
  • 5.24. IMU-131 (HER-VAXX): IMUGENE
    • 5.24.1. Product Description
    • 5.24.2. Other Developmental Activities
    • 5.24.3. Clinical Development
    • 5.24.4. Product Profile
  • 5.25. TG01 VACCINE: TARGOVAX
    • 5.25.1. Product Description
    • 5.25.2. Other Developmental Activities
    • 5.25.3. Clinical Development
    • 5.25.4. Product Profile
  • 5.26. ITI-1000 (PP65 DC VACCINE): IMMUNOMIC THERAPEUTICS
    • 5.26.1. Product Description
    • 5.26.2. Other Developmental Activities
    • 5.26.3. Clinical Development
    • 5.26.4. Product Profile

6. THERAPEUTIC ASSESSMENT

  • 6.1. MAJOR KEY PLAYERS - BASED ON NUMBER OF INDICATIONS
  • 6.2. BY PHASES
  • 6.3. BY VACCINE TYPES
  • 6.4. BY ROUTE OF ADMINISTRATION
  • 6.5. BY TARGET INDICATION OF KEY PLAYERS

7. COMPARISON OF CANCER VACCINES BY TECHNOLOGY

8. ATTRIBUTE ANALYSIS OF CANCER VACCINES

9. CANCER VACCINES: 7 MAJOR MARKET ANALYSIS

  • 9.1. KEY FINDINGS
  • 9.2. MARKET SIZE OF CANCER VACCINES IN THE 7MM
  • 9.3. UNITED STATES MARKET SIZE
    • 9.3.1. Total Market size of Cancer Vaccines
    • 9.3.2. Market Size by Therapies
  • 9.4. GERMANY MARKET SIZE
    • 9.4.1. Total Market size of Cancer Vaccines in Germany
    • 9.4.2. Market Size by Therapies
  • 9.5. FRANCE MARKET SIZE
    • 9.5.1. Total Market Size of Cancer Vaccines
    • 9.5.2. Market Size by Therapies
  • 9.6. ITALY MARKET SIZE
    • 9.6.1. Total Market Size of Cancer Vaccines
    • 9.6.2. Market Size by Therapies
  • 9.7. SPAIN MARKET SIZE
    • 9.7.1. Total Market Size of Cancer Vaccines
    • 9.7.2. Market Size by Therapies
  • 9.8. UNITED KINGDOM MARKET SIZE
    • 9.8.1. Total Market Size of Cancer Vaccines
    • 9.8.2. Market Size by Therapies
  • 9.9. JAPAN MARKET SIZE
    • 9.9.1. Total Market Size of Cancer Vaccines
    • 9.9.2. Market Size by Therapies

10. CASE REPORTS

  • 10.1. DENDREON CORPORATION FILES FOR BANKRUPTCY AS PROVENGE FAILS TO MAKE PROFITS

11. SWOT ANALYSIS FOR CANCER VACCINES

12. LIMITATIONS OF CANCER TREATMENT VACCINES

13. APPENDIX

  • 13.1. BIBLIOGRAPHY
  • REPORT METHODOLOGY

14. DELVEINSIGHT CAPABILITIES

15. DISCLAIMER

16. ABOUT DELVEINSIGHT

LIST OF TABLES

  • TABLE 1: COMPARISON OF MARKETED DRUGS
  • TABLE 2: KEY CROSS - EMERGING THERAPIES
  • TABLE 3: PROSTATAK, CLINICAL TRIAL DESCRIPTION
  • TABLE 4: TEDOPI, CLINICAL TRIAL DESCRIPTION
  • TABLE 5: DCVAC/OVCA, CLINICAL TRIAL DESCRIPTION
  • TABLE 6: DCVAC/PCA, CLINICAL TRIAL DESCRIPTION
  • TABLE 7: AXALIMOGENE FILOLISBAC (ADXS11-001; ADXS-HPV), CLINICAL TRIAL DESCRIPTION
  • TABLE 8: HEPCORTESPENLISIMUT-L, CLINICAL TRIAL DESCRIPTION
  • TABLE 9: DCVAC/LUCA, CLINICAL TRIAL DESCRIPTION
  • TABLE 10: VX-001, CLINICAL TRIAL DESCRIPTION
  • TABLE 11: TLPLDC, CLINICAL TRIAL DESCRIPTION
  • TABLE 12: MRNA-4157 + PEMBROLIZUMAB, CLINICAL TRIAL DESCRIPTION
  • TABLE 13: GRANITE (GRT-C901) + SLATE (GRT-R902), CLINICAL TRIAL DESCRIPTION
  • TABLE 14: HANK VACCINE, CLINICAL TRIAL DESCRIPTION
  • TABLE 15: GVAX, CLINICAL TRIAL DESCRIPTION
  • TABLE 16: CISPLATIN + CELECOXIB + DC VACCINE WITH OR WITHOUT RINTATOLIMOD, CLINICAL TRIAL DESCRIPTION
  • TABLE 17: POLYPEPI1018 VACCINE, CLINICAL TRIAL DESCRIPTION
  • TABLE 18: RV001V VACCINE, CLINICAL TRIAL DESCRIPTION
  • TABLE 19: SURVIVIN (DPX-SURVIVAC VACCINE), CLINICAL TRIAL DESCRIPTION
  • TABLE 20: AD-MAGEA3 AND MG1-MAGEA3, CLINICAL TRIAL DESCRIPTION
  • TABLE 21: DENDRITIC CELL BASED P53 VACCINE + NIVOLUMAB + IPILIMUMAB, CLINICAL TRIAL DESCRIPTION
  • TABLE 22: ISA101/ISA101B VACCINE, CLINICAL TRIAL DESCRIPTION
  • TABLE 23: GEN-009 ADJUVANTED VACCINE, CLINICAL TRIAL DESCRIPTION
  • TABLE 24: IMU-131 (HER-VAXX), CLINICAL TRIAL DESCRIPTION
  • TABLE 25: TG01 VACCINE, CLINICAL TRIAL DESCRIPTION
  • TABLE 26: ITI-1000 (PP65 DC VACCINE), CLINICAL TRIAL DESCRIPTION
  • TABLE 27: ASSESSMENT OF CANCER VACCINES BASED ON MAJOR KEY PLAYERS WORKING ON NUMBER OF INDICATIONS
  • TABLE 28: ASSESSMENT CANCER VACCINES BY PHASES
  • TABLE 29: ASSESSMENT OF CANCER VACCINES BY VACCINE TYPE
  • TABLE 30: ASSESSMENT OF CANCER VACCINES BY ROUTE OF ADMINISTRATION
  • TABLE 31: ASSESSMENT OF CANCER VACCINES BY INITIAL TARGET INDICATION OF KEY PLAYERS
  • TABLE 32: COMPARISON OF CANCER VACCINES BY TECHNOLOGY
  • TABLE 33: ATTRIBUTE ANALYSIS OF CANCER VACCINES
  • TABLE 34: 7 MAJOR MARKET SIZE OF CANCER VACCINES IN USD MILLION (2017-2030)
  • TABLE 35: UNITED STATES MARKET SIZE OF CANCER VACCINES , USD MILLION (2017-2030)
  • TABLE 36: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN THE UNITED STATES, IN USD MILLION (2017-2030)
  • TABLE 37: MARKET SIZE OF CANCER VACCINES IN GERMANY, IN USD MILLION (2017-2030)
  • TABLE 38: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN GERMANY, IN USD MILLION (2017-2030)
  • TABLE 39: MARKET SIZE OF CANCER VACCINES IN FRANCE, IN USD MILLION (2017-2030)
  • TABLE 40: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN FRANCE, IN USD MILLION (2017-2030)
  • TABLE 41: MARKET SIZE OF CANCER VACCINES IN ITALY, IN USD MILLION (2017-2030)
  • TABLE 42: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN ITALY, IN USD MILLION (2017-2030)
  • TABLE 43: MARKET SIZE OF CANCER VACCINES IN SPAIN, IN USD MILLION (2017-2030)
  • TABLE 44: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN SPAIN, IN USD MILLION (2017-2030)
  • TABLE 45: MARKET SIZE OF CANCER VACCINES IN THE UK, IN USD MILLION (2017-2030)
  • TABLE 46: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN THE UNITED KINGDOM, IN USD MILLION (2017-2030)
  • TABLE 47: MARKET SIZE OF CANCER VACCINES IN JAPAN, IN USD MILLION (2017-2030)
  • TABLE 48:MARKET SIZE OF CANCER VACCINES BY THERAPIES IN JAPAN, IN USD MILLION (2017-2030)

LIST OF FIGURE

  • FIGURE 1: STRATEGIES FOR CANCER VACCINE DEVELOPMENT
  • FIGURE 2: INTERACTIONS OF THE IMMUNE SYSTEM WITH WHOLE-CELL VACCINE APPROACH
  • FIGURE 3: TARGETING TSA AND TAA
  • FIGURE 4: PERSONALIZED NEOANTIGEN PEPTIDE VACCINE WORKFLOW.
  • FIGURE 5: A GENERAL WORKFLOW FOR THE PRODUCTION OF AUTOLOGOUS DENDRITIC CELL VACCINES FOR CANCER IMMUNOTHERAPY
  • FIGURE 6: ASSESSMENT OF CANCER VACCINES BASED ON MAJOR KEY PLAYERS WORKING ON NUMBER OF INDICATIONS
  • FIGURE 7: ASSESSMENT OF CANCER VACCINES BY PHASES
  • FIGURE 8: ASSESSMENT OF CANCER VACCINES BY VACCINE TYPE
  • FIGURE 9: ASSESSMENT OF CANCER VACCINES BY ROUTE OF ADMINISTRATION
  • FIGURE 10: ASSESSMENT OF CANCER VACCINES BY INITIAL TARGET INDICATION OF KEY PLAYERS
  • FIGURE 11: 7 MAJOR MARKET SIZE OF CANCER VACCINES IN USD MILLION (2017-2030)
  • FIGURE 12: MARKET SIZE OF CANCER VACCINES IN THE UNITED STATES, USD MILLIONS (2017-2030)
  • FIGURE 13: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN THE US, IN USD MILLION (2017-2030)
  • FIGURE 14: MARKET SIZE OF CANCER VACCINES IN GERMANY, USD MILLION (2017-2030)
  • FIGURE 15: MARKET SIZE OF CANCER VACCINES BY THERAPIES, IN GERMANY, IN USD MILLION (2017-2030)
  • FIGURE 16: MARKET SIZE OF CANCER VACCINES IN FRANCE, USD MILLION (2017-2030)
  • FIGURE 17: MARKET SIZE OF CANCER VACCINES BY THERAPIES, IN FRANCE, IN USD MILLION (2017-2030)
  • FIGURE 18: MARKET SIZE OF CANCER VACCINES IN ITALY, USD MILLION (2017-2030)
  • FIGURE 19: MARKET SIZE OF CANCER VACCINES BY THERAPIES, IN ITALY, IN USD MILLION (2017-2030)
  • FIGURE 20: MARKET SIZE OF CANCER VACCINES IN SPAIN, USD MILLION (2017-2030)
  • FIGURE 21: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN SPAIN, IN USD MILLION (2017-2030)
  • FIGURE 22: MARKET SIZE OF CANCER VACCINES IN THE UK, USD MILLION (2017-2030)
  • FIGURE 23: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN THE UK, IN USD MILLION (2017-2030)
  • FIGURE 24: MARKET SIZE OF CANCER VACCINES IN JAPAN, USD MILLION (2017-2030)
  • FIGURE 25: MARKET SIZE OF CANCER VACCINES BY THERAPIES IN JAPAN, IN USD MILLION (2017-2030)
  • FIGURE 26: CANCER VACCINES SWOT ANALYSIS
Back to Top